In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Belviq (Eisai)
- INDICATIONS: Obesity in adults who have at least one weight-related health condition, such as high blood pressure, Type II diabetes, or high cholesterol
- CLASS: Serotonin receptor agonist
- HALF-LIFE: ~11 hours
- FDA APPROVAL DATE: 06/27/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antipsychotics, Bupropion, Dextromethorphan, Lithium, MAO inhibitors, SNRIs, SSRIs, St John's Wort, Tramadol, Tricyclic antidepressants, Triptans
On 2/13/2020, the U.S. Food and Drug Administration (FDA) requested that the manufacturer of lorcaserin (Belviq) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
